Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial

K. Yamazaki , T. Yamanaka , M. Shiozawa , D. Manaka , M. Kotaka , M. Gamoh , A. Shiomi , A. Makiyama , Y. Munemoto , T. Rikiyama, M. Fukunaga, T. Ueki, K. Shitara, H. Shinkai, N. Tanida,

E. Oki, E. Sunami, A. Ohtsu, Y. Maehara, T. Yoshino

Ann Oncol. 2021 Jan;32(1):77-84. doi: 10.1016/j.annonc.2020.10.480.

Epub 2020 Oct 26.PMID: 33121997